Abstract: The present invention provides a combined vaccine that includes hepatitis B vaccine (HeVac) and Bacille Calmette-Guerin (BCG) for intracutaneous injection and the method of preparation of such vaccine. The combined vaccine changes the now used liquid agent of the HeVac into a cryoprotectant, thus improving the heat stability of the HBsAg. Because of the cryoprotectant in the combined vaccine, the heat stability of the HBsAg is improved, and the efficacy of the vaccine is only slightly decreased after 30 days at 37° C., and the decrease is lower than with the liquid agent of the HeVac. The present invention changes the newborn's inoculation from two injections into one to simultaneously obtain prophylaxis of hepatitis B and tuberculosis.
Type:
Grant
Filed:
May 26, 2004
Date of Patent:
August 25, 2009
Assignee:
Changchun Institute of Biological Products
Inventors:
Lijie Jin, Zhi Wang, Xiaolin Zhao, Lihua Yang, Wange Chen, Aidong Yu, Junye Sun, Fuxue Zou, Yanming Liu, Aihong Liu, Lihong Yu, Yan Cai, Manlun Yu, Yuwu Wang, Changjun Zhou, Tong Yang, Dejuan Li, Xuan Luo, Li Li
Abstract: The present invention relates to hepatitis A vaccine, especially to a lyophilized attenuated hepatitis A vaccine which can be stored at ambient temperature for extended periods of time, and to a method for producing the same. The present invention further relates to a stabilizer for lyophilized live vaccine and its use in improving thermostability of lyophilized live vaccine during lyophilization processing and storage period after lyophilization.
Type:
Grant
Filed:
October 10, 1999
Date of Patent:
April 26, 2005
Assignee:
Changchun Institute of Biological Products, Ministry of Public Health
Abstract: A combined hepatitis A-measles live vaccine, its lyophilized formulations with enhanced storage stability and methods of preparing the same by mixing the viral stocks of hepatitis A virus and measles virus or by propagating the two viruses on same diploid cell substrate are disclosed. The combined live vaccine thus prepared is a useful vaccine for preventing the infections with hepatitis A and measles without causing any interference between antigenicity of the two viruses and any serious adverse events due to their mixing or co-culturing.
Type:
Grant
Filed:
July 6, 2001
Date of Patent:
May 13, 2003
Assignee:
Changchun Institute of Biological Products, Ministry of
Public Health